Loading market movers...

Erdafitinib

Phase 3

Johnson & Johnson (JNJ)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

6 competitors in Advanced Solid Tumor

ANROLM-302 Injection

View Full Landscape

Drug Information

Target Indication

Advanced Solid Tumor

Clinical Trial

Last updated: 6/19/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/22/2024

Balversa

Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting (see section 5.1).

Drug Science

Mechanism of action & safety profile

Developer

JNJ

Johnson & Johnson

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

galantamine ERPhase 3

Alzheimer's Disease

Test acetaminophenPhase 3

Post-operative Dental Pain

CG 5503;tapentadolPhase 3

Osteoarthritis

tapentadol (CG5503) ERPhase 3

Low Back Pain

levofloxacinPhase 3

Pneumonia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts